乳腺癌患者血浆线粒体D环高变区基因突变研究  

The research for mtDNA D-loop gene mutation in plasma of primary breast cancer patients

作　　者：靳斌[1] 任军[1] 张亮[1] 汪海丹[1] 白俊[1] 张利旺[1] 斯小明[1] 

机构地区：[1]第四军医大学西京医院肿瘤中心,西安710032

出　　处：《临床肿瘤学杂志》2005年第1期1-3,10,共4页Chinese Clinical Oncology

基　　金：全国高校优秀青年教师教学科研奖励计划(TRAPOYT99-16);高等学校骨干教师资助计划(FUKT2000-06)项目

摘　　要：目的:研究检测血浆线粒体DNA基因突变对于乳腺癌诊断的参考价值。方法:选取乳腺癌患者35例,健康 对照者10人,提取血浆DNA,设计两对引物,采用聚合酶链反应(PCR)扩增血浆线粒体DNA的D环HVR1和HVR2,然后用 变性高效液相色谱法(DHPLC)对产物进行突变筛选。结果:乳腺癌患者的血浆DNA扩增率(46/140)和筛选的突变率(5/46) 与对照组比较,差异具有显著性(P<0.05)。结论:检测血浆线粒体DNA基因突变可能对于乳腺癌的诊断具有重要意义。Objective:This study was designed to identify mtDNA D-loop HVR gene mutations in plasma of primary breast cancer patients to study the clinical significance of mtDNA D-loop gene mutations associated with breast cancer.Methods:The plasma DNA in 35 primary breast cancer patients and 10 normal healthy people were extracted and mtDNA D-loop HVR1 and HVR2 fragments were amplified with designed two pairs of primers by PCR.The mutations of products were screened by denaturing high performance liquid chromatography(DHPLC).Results:Comparing with that of healthy group,amplified DNA ratio(46/140)and mutation ratio(5/46) in plasma of breast cancer have statistic means(P<0.05).Conclusion:It indicates that mtDNA gene mutations in plasma may play an important role in primary breast cancer carcinogenesis.

关 键 词：乳腺癌 血浆DNA 患者 基因突变 诊断 D环 扩增 线粒体DNA 变性高效液相色谱法 对照组 

分 类 号：R737.9[医药卫生—肿瘤] R714[医药卫生—临床医学]